Huntsman Corporation closed the sale of its Textile Effects division to Archroma, a portfolio company of SK Capital Partners, on February 28, 2023. The agreed purchase price was $593 million in cash plus assumed pension liabilities, and Huntsman
Tags :Sebastian Flückiger
As we have informed here, the AMR Action Fund, the world’s largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in BioVersys, a clinical-stage company based in Basel, Switzerland. The
VISCHER has advised EBL on the sale of its Telekom division to Sunrise. EBL has been active in the telecom business since 2000 and owns telecom networks in around 200 communities in Switzerland. At the same time,
Anaveon, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well
Vifor Pharma acquires the Swiss firm Inositec, a clinical stage biopharmaceutical company which is developing first-in-class treatments for unmet medical need. Through this acquisitions, Vifor Pharma will be spearheading the vascular calcification field to improve
MiniNaviDent has received an investment by Straumann Holding to further develop and market its Denacam system, a miniaturized dynamic navigation system for dental implants. With the investment, Straumann obtained a 39% stake of mininavident. The two
Bachem Holding, an innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides, has raised CHF 583.5 million through an accelerated bookbuilding process by issuing 750,000 new shares at a placement price of CHF 778 per
Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential
Dermavant Sciences, a clinically focused biopharmaceutical company dedicated to developing and commercializing innovative therapies in the field of immune dermatology, has signed a $160 million revenue interest purchase and sale agreement with three participants for its
The team consists of Christian Wyss (Partner, Corporate / M&A), Sebastian Flückiger (Associate, Corporate / M&A), and Adrian Briner (Associate, Tax).
